Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma11No competing interests declared.

Hanazaki, Kazuhiro; Kajikawa, Shoji; Shimozawa, Nobuhiko; Mihara, Motohiro; Shimada, Kinji; Hiraguri, Manabu; Koide, Naoki; Adachi, Wataru; Amano, Jun

doi:10.1016/s1072-7515(00)00700-6

Cited by 209 publications

(144 citation statements)

References 18 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…the cumulative probability of avoiding both death and disease recurrence) predominantly fall within the following ranges: 50-80% at 1 year, 30-50% at 3 years, 15-40% at 5 years and 8-20% at 10 years. 158,166,173,174,[176][177][178][179][180][181][182][183][184][185][186][187][188][189][190][191][192][193] …”

Section: Disease Recurrencementioning

confidence: 99%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

151

108

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: K Stein received an unrestricted grant from Schering Plough (UK) to carry out work on the cost-effectiveness of combination therapy for hepatitis C in 2000. KS is also a member of the editorial board for Health Technology Assessment, but he was not involved in the editorial process for this report. M Cramp sits on hepatitis C advisory boards for Schering Plough, Gilead and Roche. He has received unrestricted educational grants from Roche and Schering Plough to support research and service development. He has been awarded an NHS R&D grant looking at injecting drug users who do not have hepatitis C virus infection. J Thompson Coon received a grant from the Hepatitis C Trust to conduct a systematic review of complementary and alternative therapies for the treatment of chronic hepatitis C. HTA Published September 2007This report should be referenced as follows: NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, man...

show abstract

Section: Disease Recurrencementioning

confidence: 99%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

151

108

View full text Add to dashboard Cite

show abstract

“…Hepatic functional damage immediately after hepatectomy is a significant risk factor for early intrahepatic recurrence [22] . Some liver functional markers, such as alanine transaminase (ALT), gamma-glutamyl transpeptidase (GGT), serum albumin level, the preoperative indocyanine green (ICG) retention value at 15 minutes after injection, particularly the Child-Pugh classification, are important predictive markers for DFS of HCC patients [23][24][25] . According to the scoring of hepatitis activity index (HAI), the histologic activity of hepatitis was closely related to the HCC recurrence, the HCC patients with middle hepatitis activity (HAI score of 6-9) in the non-tumor liver tissue had a higher 2-year intrahepatic recurrent rate [26] .…”

Section: Co-existing Hepatitis Status and Liver Cirrhosismentioning

confidence: 99%

The prognostic significance of clinical and pathological features in hepatocellular carcinoma

Qin¹,

Tang²

2002

WJG

160

View full text Add to dashboard Cite

The prognosis of patients with HCC still remains dismal. The life expectancy of HCC patients is hard to predict because of the high possibility of postoperative recurrence. Many factors, s u c h a s p a t i e n t ' s g e n e r a l c o n d i t i o n s , macroscopic tumor morphology, as well as tumor hitopathology features, have been proven of prognostic significance. Female HCC patient often has a better prognosis than male patient, which might be due to the receptor of sex hormones. Younger patients often have tumors with higher invasiveness and metastatic potentials, and their survival and prognosis are w o r s e t h a n t h e o l d e r o n e s . C o -e x i s t i n g hepatitis status and hepatic functional reserve h a v e b e e n c o n f i r m e d a s r i s k f a c t o r s f o r recurrence. Serum alpha-fetoprotein (AFP) is useful not only for diagnosis, but also as a prognostic indicator for HCC patients. AFP mRNA has been proposed as a predictive marker of HCC cells disseminated into the circulation and for metastatic recurrence. Many pathologic features, such as tumor size, number, capsule state, cell differentiation, venous invasion, intrahepatic spreading, and a d v a n c e d p T N M s t a g e , a r e t h e b e s testablished risk factors for recurrence and important aspects affecting the prognosis of patients with HCC. Marked inflammatory cell infiltration in the tumor could predict a better prognosis. Clinical stage is still the most important factor influencing on the prognosis. E x t r a t u m o r s p r e a d i n g a n d l y m p h n o d a l metastasis are independent predictors for poor outcome. Some new predictive systems h a v e r e c e n t l y b e e n p r o p o s e d . D i f f e r e n t strategies of treatment might have significant different effects on the patients' prognosis. To date, surgical resection is still the only p o t e n t i a l l y c u r a t i v e t r e a t m e n t f o r H C C , including localized postoperative recurrences. Extent of resection, blood transfusion, occlusion of porta hepatis, and blood loss affect the survival and prognosis of HCC patients. Regional therapies provide alternative ways to improve the prognosis of HCC patients who have no opportunity to receive surgical treatment or postoperative recurrence. The combination of these treatment modalities is hopeful to further improve the prognosis. The efficacies of neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy or chemoembolization in preventing recurrence and on the HCC prognosis still remain great controversy, and deserves further evaluation. Biotherapy, including IFN-alpha therapy, will play more important role in preventing recurrence and metastasis of HCC after operation.Qin LX,Tang ZY.The prognostic significance of clinical and pathological features in hepatocellular carcinoma.

show abstract

“…These findings show bcl-xs to decrease precancerous hepatic lesions and inhibit the occurrence of hepatocellular carcinoma in rats by means of its pro-apoptotic activity. Since in humans, liver cirrhosis is known to predispose toward hepatocellular carcinoma and to frequently be associated with recurrence of liver tumors, 17,18 bcl-xs gene therapy may be effective in both preventing and inhibiting the occurrence and recurrence of liver tumors.…”

Section: Discussionmentioning

confidence: 99%

“…17,18 Therefore, in this experiment, we observed the effect of bcl-xs gene on the sequence from hepatic precancerous lesions, foci and neoplastic nodules, to hepatocellular carcinomas, which was obtained by giving rats NNM in drinking for 8 weeks. 19 Since antisense oligonucleotides are cleaved in vivo within a short time, despite chemical modification of phosphodiester linkages, 20 a higher dose than that of the plasmid or viral vectors is necessary for treatment, resulting in toxicity.…”

Section: Moreover Overexpression Of the Bcl-xs Protein Was Detectementioning

confidence: 99%

Transfer of bcl-xs plasmid is effective in preventing and inhibiting rat hepatocellular carcinoma induced by N-nitrosomorpholine

Baba

Tatsuta

2001

Gene Ther

View full text Add to dashboard Cite

Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma11No competing interests declared.

Cited by 209 publications

References 18 publications

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

The prognostic significance of clinical and pathological features in hepatocellular carcinoma

Transfer of bcl-xs plasmid is effective in preventing and inhibiting rat hepatocellular carcinoma induced by N-nitrosomorpholine

Contact Info

Product

Resources

About